Purchase Order 75N93018P00926

The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $11,475 on November 2, 2020, for immunosequencing extraction services. Work is performed in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of December 31, 2020. This award was issued to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation valued at $16,800 on September 6, 2017, with an ultimate completion date of September 14, 2017. Place of performance is Seattle, Washington. The order is for firm fixed-price immunosequencing services. No set-aside category applies.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $20,000 on July 11, 2019, with an ultimate completion date of July 11, 2020. Work is performed at Bethesda, Maryland. The order procures immunosequencing services under firm fixed-price commercial terms. No set-aside was used.</p>

<p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $308,400 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide COVID-19 funded immunoseq sequencing services for a COVID-19 research project. The contract will be performed in Seattle, Washington and has a period of performance from November 10, 2022 through May 10, 2023.</p>

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $20,000.00 on August 4, 2020. The order procures ImmunoSEQ HSTCRB_V4B service, a proprietary immunosequencing assay that quantitatively assesses the breadth and complexity of clonal T- or B-cell populations to screen healthy controls and support research objectives. Performance is located in Seattle, Washington. The purchase order is firm fixed price with...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Adaptive Biotechnologies Corporation for DNA extraction services (ImmunoSEQ) valued at $21,225.00 on September 15, 2021. Performance is located in Bethesda, Maryland. The order is priced on a firm fixed-price basis with no small business set-aside. The ultimate completion date is January 7, 2022. This purchase order supports the FY26 UDO Initiative DNA Extraction Services requirement and procures...

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,690 firm fixed-price purchase order to Adaptive Biotechnologies Corporation (doing business as Adaptive) for ImmunoSEQ sequencing services. The contract has an ultimate completion date of December 20, 2024. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts and grants from the Department of Health and Human Services (HHS), Department...

This is a $12,300 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (Adaptive) for &quot;IMMUNOSEQ MMTCRB SEQUENCING SERVICE&quot;. The contract has an ultimate completion date of December 31, 2023 and was awarded on September 19, 2023 without a set-aside designation. Adaptive, a for-profit organization, has previously...

This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Adaptive Biotechnologies Corporation (also doing business as Adaptive) for IMMUNOSEQ MMTCRB SERVICE. The contract, valued at $12,200.00, does not have a set-aside designation. Through this award, Adaptive Biotechnologies will provide specialized sequencing and testing services to support HHS research programs. Adaptive...

The Department of Health and Human Services (HHS) National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $61,150.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for SARS-COV-2 immunosequencing testing services. The contract has a performance period through September 30, 2024 and was awarded on May 7, 2024. Adaptive has previously provided specialized testing and genomic sequencing services to HHS,...